KCT0009698尚未招募Unknown
The first line Lazertinib treatment for metastatic EGFRm NSCLC; the real world evidence in South Korea
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Age = 18 years old and holding Korean (nationality) at the time of Informed consent
- •2) Voluntarily signed the informed consent form
- •However, WGS(whole genome sequencing) test will only conducted on individuals who have voluntarily singed a separated consent form.
- •3) Patients who are to initiate lazertinib as the first line treatment
- •? EGFR L858R or 19del mutation-positive stage IV NSCLC patients,
- •? or Patients with EGFR L858R or 19del mutation-positive NSCLC who relapsed to stage 4 after surgery and had no history of EGFR-TKI treatment (neoadjuvant/adjuvant chemotherapy/radiotherapy before/after surgery is allowed)
排除标准
- •1) Age < 18 years old
- •2) histologically or cytologically not confirmed NSCLC
- •3) No EGFR L858R or 19del mutation
- •4) Not receiving lazertinib as first-line treatment
- •5) No agreement to participate in this study
- •6) Anticipated subject unable to complete the research as determined by the PI and Sub-I.
- •7) Patients enrolled in other studies related to lazertinib (Duplicate enrollment in other studies involving lazertinib was not allowed.)
研究者
相似试验
招募中
1 期
Phase I trial of S-1 with Lapatinb for metastatic breast cancermetastatic breast cancerJPRN-UMIN000003583St. Luke's International Hospital18
进行中（未招募）
1 期
Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumabmetastatic colorectal cancerMedDRA version: 20.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864EUCTR2009-013099-38-DEKlinikum der Universität München, Anstalt des öffentlichen Rechts vertreten durch den Vorstand450
进行中（未招募）
2 期
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsNCT05807880Sun Yat-sen University59
进行中（未招募）
不适用
Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®)metastasiertes MammakarzinomMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2005-004234-41-DEOtto-von-Guericke Universität Magdeburg
尚未招募
Unknown
eoadjuvant lazertinib with or without chemotherapy for patients with EGFR-mutated resectable non-small cell lung cancer (NeoLazer): a phase II, randomized, multi-center studyNeoplasmsKCT0009313Yonsei University Health System, Severance Hospital160